Distinguished in Gastrointestinal Bleeding

Dr. Mohammad M. Jamal

Gastroenterology
26501 Rancho Parkway South, Suite 103, 
Lake Forest, CA 
Accepting New Patients
Offers Telehealth
Distinguished in Gastrointestinal Bleeding
26501 Rancho Parkway South, Suite 103, 
Lake Forest, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mohammad Jamal is a Gastroenterologist in Lake Forest, California. Dr. Jamal is rated as a Distinguished provider by MediFind in the treatment of Gastrointestinal Bleeding. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Gastrointestinal Bleeding, Gallstones, Endoscopy, and Gastrectomy. Dr. Jamal is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in NV
Hospital Affiliations
Memorialcare Saddleback Medical Center
Corona Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

26501 Rancho Parkway South, Suite 103, Lake Forest, CA 92630

Additional Areas of Focus

Dr. Jamal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 306)
Enrollment Status: Terminated
Publish Date: May 11, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction
Enrollment Status: Completed
Publish Date: February 11, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
Enrollment Status: Completed
Publish Date: April 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

4 Total Publications

Mirizzi-Induced Bouveret's Syndrome: Revelations of Timely Surgical Intervention.
Mirizzi-Induced Bouveret's Syndrome: Revelations of Timely Surgical Intervention.
Journal: Case reports in gastroenterology
Published: September 27, 2021
Similar Doctors
Elite in Gastrointestinal Bleeding
Dr. Ian M. Gralnek
Gastroenterology
Elite in Gastrointestinal Bleeding
Dr. Ian M. Gralnek
Gastroenterology
200 Medical Plaza, #365,530,420,120, 
Los Angeles, CA 
 (52.4 miles away)
310-794-9718
Languages Spoken:
English

Ian Gralnek is a Gastroenterologist in Los Angeles, California. Dr. Gralnek is rated as a Distinguished provider by MediFind in the treatment of Gastrointestinal Bleeding. Her top areas of expertise are Gastrointestinal Bleeding, Esophageal Varices, Portal Hypertension, Endoscopy, and Colonoscopy.

Distinguished in Gastrointestinal Bleeding
Dr. Gustavo Machicado
Gastroenterology
Distinguished in Gastrointestinal Bleeding
Dr. Gustavo Machicado
Gastroenterology

United Medical Doctors

40663 Murrieta Hot Springs Rd, Suite C1, 
Murrieta, CA 
 (29.5 miles away)
951-200-6791
Languages Spoken:
English
See accepted insurances

Gustavo Machicado is a Gastroenterologist in Murrieta, California. Dr. Machicado is rated as a Distinguished provider by MediFind in the treatment of Gastrointestinal Bleeding. His top areas of expertise are Gastrointestinal Bleeding, Gastritis, Chronic Erosive Gastritis, Endoscopy, and Gastrectomy.

Distinguished in Gastrointestinal Bleeding
Dr. Kevin Ghassemi
Gastroenterology
Distinguished in Gastrointestinal Bleeding
Dr. Kevin Ghassemi
Gastroenterology

The Regents Of The University Of California

100 Medical Plaza, 
Los Angeles, CA 
 (52.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Ghassemi is a Gastroenterologist in Los Angeles, California. Dr. Ghassemi is rated as a Distinguished provider by MediFind in the treatment of Gastrointestinal Bleeding. His top areas of expertise are Gastrointestinal Bleeding, Achalasia, Swallowing Difficulty, Endoscopy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jamal's expertise for a condition
ConditionClose
    View All 32 Distinguished Conditions
    View All 71 Advanced Conditions
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile